These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37568977)

  • 21. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
    Pandit-Taskar N; Veach DR; Fox JJ; Scher HI; Morris MJ; Larson SM
    J Nucl Med; 2016 Oct; 57(Suppl 3):73S-78S. PubMed ID: 27694177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
    Vargas HA; Wassberg C; Fox JJ; Wibmer A; Goldman DA; Kuk D; Gonen M; Larson SM; Morris MJ; Scher HI; Hricak H
    Radiology; 2014 Apr; 271(1):220-9. PubMed ID: 24475817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer.
    Lazari M; Lyashchenko SK; Burnazi EM; Lewis JS; van Dam RM; Murphy JM
    Appl Radiat Isot; 2015 Sep; 103():9-14. PubMed ID: 26046518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals.
    Zhou D; Lin M; Yasui N; Al-Qahtani MH; Dence CS; Schwarz S; Katzenellenbogen JA
    J Labelled Comp Radiopharm; 2014 May; 57(5):371-7. PubMed ID: 24861984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET).
    Bertolini R; Goepfert C; Andrieu T; Nichols S; Walter MA; Frey FJ; McCammon JA; Frey BM
    Prostate; 2015 Mar; 75(4):348-59. PubMed ID: 25358634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen Receptor Imaging in the Management of Hormone-Dependent Cancers with Emphasis on Prostate Cancer.
    Kairemo K; Hodolic M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing imaging strategies for castration resistant prostate cancer.
    Fox JJ; Morris MJ; Larson SM; Schöder H; Scher HI
    Acta Oncol; 2011 Jun; 50 Suppl 1(Suppl 1):39-48. PubMed ID: 21604939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthy Tissue Uptake of
    Jansen BHE; Kramer GM; Cysouw MCF; Yaqub MM; de Keizer B; Lavalaye J; Booij J; Vargas HA; Morris MJ; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2019 Aug; 60(8):1111-1117. PubMed ID: 30630941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorine-18 Labeled Fluorofuranylnorprogesterone ([
    Basuli F; Zhang X; Blackman B; White ME; Jagoda EM; Choyke PL; Swenson RE
    Molecules; 2019 Jun; 24(13):. PubMed ID: 31261651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
    Rathkopf DE; Morris MJ; Fox JJ; Danila DC; Slovin SF; Hager JH; Rix PJ; Chow Maneval E; Chen I; Gönen M; Fleisher M; Larson SM; Sawyers CL; Scher HI
    J Clin Oncol; 2013 Oct; 31(28):3525-30. PubMed ID: 24002508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Head-to-Head Comparison between FDG and
    Filippi L; Frantellizzi V; Bartoletti P; Vincentis G; Schillaci O; Evangelista L
    Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
    Fox JJ; Autran-Blanc E; Morris MJ; Gavane S; Nehmeh S; Van Nuffel A; Gönen M; Schöder H; Humm JL; Scher HI; Larson SM
    J Nucl Med; 2011 Nov; 52(11):1727-32. PubMed ID: 21984797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
    BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.
    Filippi L; Frantellizzi V; Chiaravalloti A; Pontico M; De Feo MS; Corica F; Montebello M; Schillaci O; De Vincentis G; Bagni O
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
    Simoncic U; Perlman S; Liu G; Jeraj R
    Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with
    Wibmer AG; Morris MJ; Gonen M; Zheng J; Hricak H; Larson S; Scher HI; Vargas HA
    J Nucl Med; 2021 Aug; 62(8):1050-1056. PubMed ID: 33419944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Applications of TSPO PET for Glioma Imaging: Current Evidence and Future Perspective-A Systematic Review.
    Filippi L; Frantellizzi V; Vincentis G; Schillaci O; Evangelista L
    Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.